Published in Curr Opin Nephrol Hypertens on March 01, 2015
The Impact of Kidney Development on the Life Course: A Consensus Document for Action. Nephron (2017) 0.82
Endothelial cell dysfunction and cardiac hypertrophy in the STOX1 model of preeclampsia. Sci Rep (2016) 0.77
A best practice position statement on the role of the nephrologist in the prevention and follow-up of preeclampsia: the Italian study group on kidney and pregnancy. J Nephrol (2017) 0.77
A Dormant Microbial Component in the Development of Preeclampsia. Front Med (Lausanne) (2016) 0.76
Establishment of ApoE-knockout mouse model of preeclampsia and relevant mechanisms. Exp Ther Med (2016) 0.75
A liposomal Gd contrast agent does not cross the mouse placental barrier. Sci Rep (2016) 0.75
Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines. Clin J Am Soc Nephrol (2016) 0.75
Angiogenesis-Related Biomarkers (sFlt-1/PLGF) in the Prediction and Diagnosis of Placental Dysfunction: An Approach for Clinical Integration. Int J Mol Sci (2015) 0.75
Serum Adipsin Levels throughout Normal Pregnancy and Preeclampsia. Sci Rep (2016) 0.75
Hypertensive disorders of pregnancy: what the physician needs to know. Cardiovasc J Afr (2016) 0.75
Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction. Hypertens Res (2016) 0.75
Hypertensive disorders in pregnancy. World J Nephrol (2016) 0.75
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 9.87
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int (2002) 8.03
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 6.41
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2007) 5.26
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol (2008) 3.82
Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med (2006) 3.72
Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol (2009) 3.40
Cord-blood 25-hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma. Pediatrics (2010) 3.39
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 3.33
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol (2008) 2.96
Effects of phosphate binders in moderate CKD. J Am Soc Nephrol (2012) 2.92
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int (2012) 2.74
Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia. Hypertension (2013) 2.70
Pathogenesis of preeclampsia. Annu Rev Pathol (2010) 2.66
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension (2007) 2.62
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis (2009) 2.34
Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. Crit Care Med (2012) 2.32
Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol (2014) 2.30
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension (2005) 2.22
Early outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol (2011) 2.17
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) (2009) 2.10
Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol (2009) 2.09
Preeclampsia and angiogenic imbalance. Annu Rev Med (2008) 2.05
Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol (2005) 2.04
Transesophageal echocardiography improves risk assessment of thrombolysis of prosthetic valve thrombosis: results of the international PRO-TEE registry. J Am Coll Cardiol (2004) 2.03
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol (2005) 2.03
Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension (2006) 2.02
Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol (2009) 1.95
Molecular mechanisms of preeclampsia. Microvasc Res (2007) 1.90
PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest (2011) 1.88
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88
Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension (2012) 1.86
Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation (2009) 1.85
Shorter dialysis times are associated with higher mortality among incident hemodialysis patients. Kidney Int (2010) 1.83
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension (2009) 1.82
Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol (2007) 1.80
First trimester insulin resistance and subsequent preeclampsia: a prospective study. J Clin Endocrinol Metab (2002) 1.79
Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res (2005) 1.78
Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis (2012) 1.72
Uric acid, endothelial dysfunction and pre-eclampsia: searching for a pathogenetic link. J Hypertens (2004) 1.71
Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol (2005) 1.71
Postpartum diabetes screening in women with a history of gestational diabetes. Obstet Gynecol (2005) 1.70
Genetic variation in APOL1 associates with younger age at hemodialysis initiation. J Am Soc Nephrol (2011) 1.70
Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol (2007) 1.69
Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract (2007) 1.67
Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol (2007) 1.67
Metabolite profiling identifies markers of uremia. J Am Soc Nephrol (2010) 1.63
Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia. Arthritis Rheumatol (2015) 1.61
Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ (2009) 1.59
Angiogenic factors and preeclampsia. Semin Nephrol (2011) 1.58
Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension (2007) 1.56
VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med (2008) 1.54
Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem (2002) 1.51
The glomerular injury of preeclampsia. J Am Soc Nephrol (2007) 1.50
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J Natl Cancer Inst (2006) 1.49
Nutritional vitamin D in dialysis patients: what to D-iscern? Nephrol Dial Transplant (2011) 1.49
Inverse relationship between long-chain n-3 fatty acids and risk of sudden cardiac death in patients starting hemodialysis. Kidney Int (2013) 1.48
Familial factors in the association between preeclampsia and later ESRD. Clin J Am Soc Nephrol (2012) 1.47
Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes. Clin J Am Soc Nephrol (2010) 1.44
Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int (2004) 1.42
First-trimester C-reactive protein and subsequent gestational diabetes. Diabetes Care (2003) 1.41
First trimester vitamin D, vitamin D binding protein, and subsequent preeclampsia. Hypertension (2010) 1.39
Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem (2005) 1.36
Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults. J Allergy Clin Immunol (2011) 1.35
Pregnancy and the kidney. J Am Soc Nephrol (2008) 1.34